Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01193842 · OUTCOME

Event-free Survival (EFS) (Phase II)

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas · Source last updated 2023-11-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
1 year

What was measured

The percentage of participants surviving without events (relapse or death) one year after starting treatment.

Analysis population: Eligible randomized participants.

Groups in this outcome

Phase II: VR-DA-EPOCH

Arm A (VR-DA-EPOCH) at the recommended phase II dose of Vorinostat (300 mg once a day for days 1-5 of a cycle)

Phase II: DA-R-EPOCH

Arm B (DA-R-EPOCH), which is the same treatment as Arm A, but without Vorinostat

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase II: VR-DA-EPOCH45
Phase II: DA-R-EPOCH45

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Phase II: VR-DA-EPOCH75.6Not reported63.088.1Not reported
Phase II: DA-R-EPOCH82.2Not reported71.193.4Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        63.0
        upper Limit
        88.1
        value
        75.6
      2. group Id
        OG001
        lower Limit
        71.1
        upper Limit
        93.4
        value
        82.2
denoms
  1. counts
    1. group Id
      OG000
      value
      45
    2. group Id
      OG001
      value
      45
    units
    Participants
description
The percentage of participants surviving without events (relapse or death) one year after starting treatment.
dispersion Type
95% Confidence Interval
groups
  1. description
    Arm A (VR-DA-EPOCH) at the recommended phase II dose of Vorinostat (300 mg once a day for days 1-5 of a cycle)
    id
    OG000
    title
    Phase II: VR-DA-EPOCH
  2. description
    Arm B (DA-R-EPOCH), which is the same treatment as Arm A, but without Vorinostat
    id
    OG001
    title
    Phase II: DA-R-EPOCH
param Type
NUMBER
population Description
Eligible randomized participants.
reporting Status
POSTED
time Frame
1 year
title
Event-free Survival (EFS) (Phase II)
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice